Neurocrine Pays $2.9B for a Drug That Sells Itself at $466K a Year
The neuroscience company is buying Soleno Therapeutics at a 34% premium to lock up Vykat XR, the only approved treatment for the insatiable hunger of Prader-Willi syndrome, with just 12.5% of patients reached so far.
Deal Overview
Neurocrine Biosciences (NASDAQ: NBIX) announced on April 6 that it will acquire Soleno Therapeutics (NASDAQ: SLNO) for $53 per share in an all-cash tender offer, valuing Soleno at approximately $2.9 billion. The offer represents a 34% premium to Soleno’s closing price on April 2 and a 51% premium to its 30-day volume-weighted average price. Neurocrine will fund the deal with its $2.54 billion cash pile supplemented by modest pre-payable debt. The transaction is expected to close within 90 days.
Soleno’s Vykat XR (diazoxide choline) was approved by the FDA in March 2025 as the first and only treatment for hyperphagia in Prader-Willi syndrome. In its first nine months on market, the drug generated $190.4 million in net revenue, priced at $466,000 per patient per year. By year-end 2025, 859 patients were actively on drug, representing just 12.5% of the estimated U.S. addressable market.
Why It Matters
The commercial proof point: Neurocrine is buying a proven asset with enormous room to run. Vykat XR has 630 active prescribers and only 12.5% market penetration. Layering it onto Neurocrine’s existing rare disease sales force from its Ingrezza franchise is the kind of deal that pays for itself through distribution leverage alone.
The “surprising” price: Stifel analysts flagged the deal as unexpectedly cheap for Soleno shareholders given the drug’s trajectory. At roughly 15x trailing revenue for a product with 87.5% of its market still untapped, Soleno’s board may face questions about whether it left money on the table.
- Payer resistance at scale: Vykat XR costs $466K/year. Coverage currently reaches 60% of U.S. lives. Pushing deeper into Medicaid and smaller plans will test pricing power.
- Small patient population: PWS affects roughly 1 in 15,000 births. Even at full penetration, this is a niche market.
- 87.5% of patients untouched: Only 12.5% of the U.S. addressable market has been reached in nine months. The penetration curve is still steep.
- Orphan drug economics: First-in-class, no competition, 7 years of market exclusivity remaining.